Literature DB >> 21695413

The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis.

Yukihiko Kawasaki1.   

Abstract

Henoch-Schönlein purpura (HSP) is a systemic disorder characterized by leukocytoclastic vasculitis involving the capillaries and the deposition of IgA immune complexes. Renal involvement is the principal cause of morbidity and mortality in children with HSP. Thus, it is important to clarify the onset mechanism of Henoch-Schönlein purpura nephritis (HSPN) and to identify the most appropriate treatment. We herein review the pathogenesis and treatment of HSPN. As to the pathogenesis, several studies suggest that galactose-deficient IgA1 is recognized by anti-glycan antibodies, leading to the formation of circulating immune complexes and their mesangial deposition, thereby inducing renal injury. Aggressive therapies for the treatment of severe HSPN, including multiple drug combination therapy and plasmapheresis, have been shown to be effective in ameliorating proteinuria and histological severity. Nevertheless, detailed investigations of the pathogenesis of HSPN and double-blind randomized control studies on children with HSPN are still necessary.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21695413     DOI: 10.1007/s10157-011-0478-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  61 in total

Review 1.  Immunoregulatory drugs: mechanistic basis for use in organ transplantation.

Authors:  M Suthanthiran; T B Strom
Journal:  Pediatr Nephrol       Date:  1997-10       Impact factor: 3.714

Review 2.  Mizoribine and mycophenolate mofetil.

Authors:  H Ishikawa
Journal:  Curr Med Chem       Date:  1999-07       Impact factor: 4.530

Review 3.  IgA: an immune glycoprotein.

Authors:  Esther M Yoo; Sherie L Morrison
Journal:  Clin Immunol       Date:  2005-07       Impact factor: 3.969

4.  Intravenous immunoglobulin in Henoch-Schönlein purpura: a case study.

Authors:  F J Heldrich; S Minkin; C L Gatdula
Journal:  Md Med J       Date:  1993-06

5.  Activation of the lectin complement pathway in Henoch-Schönlein purpura nephritis.

Authors:  Satoshi Hisano; Misao Matsushita; Teizo Fujita; Hiroshi Iwasaki
Journal:  Am J Kidney Dis       Date:  2005-02       Impact factor: 8.860

6.  Methylprednisolone pulse plus mizoribine in children with Henoch-Schoenlein purpura nephritis.

Authors:  Yukihiko Kawasaki; Kazuhide Suyama; Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Clin Rheumatol       Date:  2010-09-16       Impact factor: 2.980

7.  Renal biopsy 2-9 years after Henoch Schönlein purpura.

Authors:  Carmen Algoet; Willem Proesmans
Journal:  Pediatr Nephrol       Date:  2003-04-03       Impact factor: 3.714

Review 8.  Recurrent diseases in the renal allograft.

Authors:  E L Ramos
Journal:  J Am Soc Nephrol       Date:  1991-08       Impact factor: 10.121

Review 9.  The glomerular response to IgA deposition in IgA nephropathy.

Authors:  Ivan C Moura; Marc Benhamou; Pierre Launay; François Vrtovsnik; Ulrich Blank; Renato C Monteiro
Journal:  Semin Nephrol       Date:  2008-01       Impact factor: 5.299

Review 10.  Mizoribine: a new approach in the treatment of renal disease.

Authors:  Yukihiko Kawasaki
Journal:  Clin Dev Immunol       Date:  2009-12-13
View more
  26 in total

Review 1.  Pediatric vasculitis.

Authors:  Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

2.  What should be the indications for fibrinolytic therapy in children with severe Henoch-Schönlein purpura nephritis?

Authors:  Se Jin Park; Jae Il Shin
Journal:  Clin Exp Nephrol       Date:  2012-02-14       Impact factor: 2.801

3.  Urinary MCP-1/creatinine in Henoch-Schönlein purpura and its relationship with nephritis.

Authors:  Yolanda Fuentes; Ana María Hernández; Pilar García-Roca; Saúl Valverde; Luis Fernando Velásquez-Jones; Germán Sosa; Uriel Oswaldo Duarte-Durán; Lourdes Ortíz; Rocío Maldonado; Enrique Faugier; Guillermo Ramón-García; Mara Medeiros
Journal:  Pediatr Nephrol       Date:  2014-01-12       Impact factor: 3.714

4.  Staphylococcus Infection-Associated GN - Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort.

Authors:  Anjali A Satoskar; Sarah Suleiman; Isabelle Ayoub; Jessica Hemminger; Samir Parikh; Sergey V Brodsky; Cherri Bott; Edward Calomeni; Gyongyi M Nadasdy; Brad Rovin; Lee Hebert; Tibor Nadasdy
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 8.237

5.  The incidence and severity of IgA vasculitis with nephritis over a 10-year period in our hospital.

Authors:  Keishi Yamane; Yukihiko Kawasaki; Ryo Maeda; Shinichiro Ohara; Kazuhide Suyama; Mitsuaki Hosoya
Journal:  Fukushima J Med Sci       Date:  2017-09-14

6.  Application value of laboratory indexes in the differential diagnosis of Henoch-Schoenlein purpura.

Authors:  W-X Shao; Q Ye; X-J Wang
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

7.  Macrophage migration inhibitory factor urinary excretion revisited – MIF a potent predictor of the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis.

Authors:  Rafał Zwiech
Journal:  BMC Immunol       Date:  2015-08-14       Impact factor: 3.615

Review 8.  Recent understanding on diagnosis and management of central nervous system vasculitis in children.

Authors:  Ludovico Iannetti; Roberta Zito; Simone Bruschi; Laura Papetti; Fiorenza Ulgiati; Francesco Nicita; Francesca Del Balzo; Alberto Spalice
Journal:  Clin Dev Immunol       Date:  2012-09-12

9.  Beneficial effects of creatine phosphate sodium for the treatment of Henoch-Schönlein purpura in patients with early renal damage detected using urinary kidney injury molecule-1 levels.

Authors:  Jianjiang Zhang; Huiqin Zeng; Na Wang; Xiyan Tian; Wenjie Dou; Peipei Shi
Journal:  Eur J Pediatr       Date:  2015-07-30       Impact factor: 3.860

10.  Association between Tfh and PGA in children with Henoch-Schönlein purpura.

Authors:  Miao Meihua; Li Xiaozhong; Wang Qin; Zhu Yunfen; Cui Yanyan; Shao Xunjun
Journal:  Open Med (Wars)       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.